Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) can cause severe and lethal bronchiolitis and pneumonia among particularly vulnerable populations, mostly infants, the elderly and immunocompromised patients. Researchers from Vanderbilt University Medical Center have isolated and characterized novel antibodies that cross-neutralize RSV and hMPV.
Merck Sharp & Dohme LLC has synthesized viral replication inhibitors reported to be useful for the treatment of respiratory syncytial virus and metapneumovirus infections.
Vicebio Ltd. is funded to take two of its molecular clamp respiratory infection vaccines through phase II development, after raising $100 million in a series B.
Merck Sharp & Dohme LLC has patented compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) and metapneumovirus (MPV) infections.
Enanta Pharmaceuticals Inc. has patented heterocyclic compounds potentially useful for the treatment of metapneumovirus (MPV), influenza and respiratory syncytial virus (RSV) infections.
Enanta Pharmaceuticals Inc. has presented heterocyclic compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) and metapneumovirus (MPV) infections.
